Why the study?
Does saralasin infusion affect blood pressure and renal vascular resistance in conscious normotensive and hypertensive dogs, and is this mediated by adrenergic receptors?
Does saralasin infusion affect blood pressure and renal vascular resistance in conscious normotensive and hypertensive dogs, and is this mediated by adrenergic receptors?
The transient agonist response to saralasin in conscious dogs is likely mediated by direct action on vascular angiotensin receptors rather than adrenergic pathways.
Indicates non-adrenergic mediation of saralasin effects in dogs; hypothesis-generating with no current implications for human practice.
In the conscious normotensive and two-kidney Goldblatt hypertensive dog a transient agonist response to the intravenous infusion of saralasin (1 microgram min-1 kg-1)was manifested by a small increase in blood pressure (6-12) mmHg) and 28-30% increase in renal vascular resistance. 2. These increases in blood pressure and renal vascular resistance were unaffected by administration of either phentolamine or guanethidine. 3. The agonist response in the conscious dog is most likely accounted for by a direct action of saralasin on vascular angiotensin receptors.
No takes yet. Share an insight, caveat, or question.
Ben G. Zimmerman (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: